Calithera Biosciences Inc. (NASDAQ: CALA) is -55.19% lower on its value in year-to-date trading and has touched a low of $2.03 and a high of $7.42 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CALA stock was last observed hovering at around $2.32 in the last trading session, with the day’s loss setting it -0.12% off its average median price target of $4.00 for the next 12 months. It is also 78.0% off the consensus price target high of $10.00 offered by 6 analysts, but current levels are -10.0% lower than the price target low of $2.00 for the same period.
Currently trading at $2.20, the stock is -3.53% and -15.17% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.66 million and changing -5.17% at the moment leaves the stock -40.45% off its SMA200. CALA registered -65.19% loss for a year compared to 6-month loss of -39.89%. The firm has a 50-day simple moving average (SMA 50) of $2.7952 and a 200-day simple moving average (SMA200) of $3.6449.
The stock witnessed a -9.84% gain in the last 1 month and extending the period to 3 months gives it a -24.40%, and is 1.85% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.63% over the week and 5.48% over the month.
Distance from 52-week low is 8.37% and -70.35% from its 52-week high.
Calithera Biosciences Inc. (CALA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Calithera Biosciences Inc. (CALA) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.70, where 1 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Calithera Biosciences Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.28.The EPS is expected to grow by 31.00% this year.
Calithera Biosciences Inc. (CALA) Top Institutional Holders
155 institutions hold shares in Calithera Biosciences Inc. (CALA), with 517.62k shares held by insiders accounting for 0.71% while institutional investors hold 79.04% of the company’s shares. The shares outstanding are 70.60M, and float is at 69.84M with Short Float at 3.22%. Institutions hold 78.49% of the Float.
The top institutional shareholder in the company is Primecap Management Company with over 10.25 million shares valued at $50.34 million. The investor’s holdings represent 13.85% of the CALA Shares outstanding. As of Dec 30, 2020, the second largest holder is Federated Hermes, Inc. with 7.44 million shares valued at $36.54 million to account for 10.05% of the shares outstanding. The other top investors are Blackrock Inc. which holds 5.67 million shares representing 7.66% and valued at over $27.83 million, while BVF Inc. holds 5.89% of the shares totaling 4.36 million with a market value of $21.41 million.
Calithera Biosciences Inc. (CALA) Insider Activity
A total of 16 insider transactions have happened at Calithera Biosciences Inc. (CALA) in the last six months, with sales accounting for 1 and purchases happening 15 times. The most recent transaction is an insider sale by Orford Keith, the company’s Chief Medical Officer. SEC filings show that Orford Keith sold 2,447 shares of the company’s common stock on Dec 16 at a price of $6.00 per share for a total of $14682.0. Following the sale, the insider now owns 11094.0 shares.
Calithera Biosciences Inc. disclosed in a document filed with the SEC on May 21 that BVF PARTNERS L P/IL (10% Owner) sold a total of 2,283,598 shares of the company’s common stock. The trade occurred on May 21 and was made at $6.00 per share for $13.7 million. Following the transaction, the insider now directly holds 0.48 million shares of the CALA stock.
Calithera Biosciences Inc. (CALA): Who are the competitors?
The company’s main competitors (and peers) include Eloxx Pharmaceuticals Inc. (ELOX) that is trading -32.39% down over the past 12 months. Pieris Pharmaceuticals Inc. (PIRS) is -22.18% down on the 1-year trading charts. Short interest in the company’s stock has fallen -23.63% from the last report on Apr 14, 2021 to stand at a total of 2.25 million short shares sold with a short interest ratio of 2.55.